C25-140
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564689

CAS#: 1358099-18-9

Description: C25-140 is the first in class protein-protein interaction inhibitor of a RING-E3 ligase (TRAF6) / E2 enzyme (Ubc13) binding.


Price and Availability

Size
Price

50mg
USD 850
500mg
USD 2650
Size
Price

100mg
USD 1450
1g
USD 3650
Size
Price

200mg
USD 1950
2g
USD 5450

C25-140, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 564689
Name: C25-140
CAS#: 1358099-18-9
Chemical Formula: C26H31N7O
Exact Mass: 457.259
Molecular Weight: 457.58
Elemental Analysis: C, 68.25; H, 6.83; N, 21.43; O, 3.50


Synonym: C25140; C-25140; C 25140; C25 140; C25-140; C-25-140;

IUPAC/Chemical Name: 1-(4-Benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one

InChi Key: HFKVRXVHZGBRKF-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H31N7O/c1-18-23(19(2)32(29-18)25-11-10-24-28-27-20(3)33(24)30-25)9-12-26(34)31-15-13-22(14-16-31)17-21-7-5-4-6-8-21/h4-8,10-11,22H,9,12-17H2,1-3H3

SMILES Code: O=C(N1CCC(CC2=CC=CC=C2)CC1)CCC3=C(C)N(C4=NN5C(C=C4)=NN=C5C)N=C3C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


References

1: Brenke JK, Popowicz GM, Schorpp K, Rothenaigner I, Roesner M, Meininger I, Kalinski C, Ringelstetter L, R'kyek O, Jürjens G, Vincendeau M, Plettenburg O, Sattler M, Krappmann D, Hadian K. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293(34):13191-13203. doi: 10.1074/jbc.RA118.002649. Epub 2018 Jun 27. PubMed PMID: 29950522; PubMed Central PMCID: PMC6109917.